{"id":"W4408140991","doi":"10.1016/s2352-3018(24)00344-8","title":"Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study","year":2025,"lang":"en","type":"article","venue":"The Lancet HIV","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Child Health and Human Development; National Institute of Allergy and Infectious Diseases; National Institute of Mental Health; National Institutes of Health","keywords":"Rilpivirine; Medicine; Human immunodeficiency virus (HIV); Pharmacology; Dolutegravir; Maximum tolerated dose; Phases of clinical research; Oncology; Adverse effect; Virology; Internal medicine; Antiretroviral therapy; Viral load; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007778563,0.0003880674,0.001322662,0.0002270156,0.0004929099,0.00008353753,0.000452979,0.0001158584,0.00003766052],"category_scores_gemma":[0.0001268794,0.0002585246,0.00003472196,0.0009055692,0.0001330284,0.0002510164,0.0003196172,0.0007470145,0.00001796099],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000188406,"about_ca_system_score_gemma":0.0002234974,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007837212,"about_ca_topic_score_gemma":0.0006857094,"domain_scores_codex":[0.9972783,0.0003152254,0.0008181608,0.0006154514,0.0002734838,0.0006993812],"domain_scores_gemma":[0.9980717,0.0003437048,0.0004765787,0.0008027233,0.0001475755,0.0001577145],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01717276,0.009461805,0.9621782,0.0004635476,0.0004676303,0.0001787456,0.004675622,0.0002517557,0.002727061,0.00005934775,0.0002789142,0.002084591],"study_design_scores_gemma":[0.1102986,0.002748182,0.866475,0.003498144,0.0004885912,0.00004439136,0.003075905,0.01185623,0.0009677889,0.00003992121,0.0001200873,0.0003870823],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.989112,0.0002678708,0.0005540119,0.0008827168,0.00005656691,0.004202126,0.00004159033,0.00006183266,0.00482124],"genre_scores_gemma":[0.9977542,0.0000876144,0.0008913968,0.0002177246,0.00003672166,0.000193493,0.00007397625,0.00002855491,0.0007163181],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09570315,"threshold_uncertainty_score":0.9999867,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06715696422115511,"score_gpt":0.3883279035400025,"score_spread":0.3211709393188473,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}